Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer.

Prostate Int · 2021 · PMC8498729 · PMID 34692582

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

16 Data from ENZAMET in patients with previous local treatment showed a trend toward better overall survival (HR: 0.72; CI: 0.47–1.09) and significantly longer clinical progression-free survival (HR: 0.42; CI: 0.31–0.57) for the addition of enzalutamide to ADT. 15 In conclusion, enzalutamide represents an option for synchronous and metachronous omHSPC.

also in 53,322 other papers

failed to reach significanceno p-value reported

However, Hove improvement in overall survival closely failed to reach significance (HR: 0.40; CI: 0.15–1.03), which again might be caused by the few events (n = 18) that occurred in this small subgroup (n = 144). 14 In brief, the addition of apalutamide to ADT offers a therapeutic option for synchronous and metachronous omHSPC patients. 3.2.3.

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.